v3.25.1
Note 6 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities (in shares) 0 250
Convertible Series F Preferred Stock [Member]    
Antidilutive Securities (in shares) [1] 52,512 98,689
Series F Preferred Warrants [Member]    
Antidilutive Securities (in shares) [2] 2,784,921 2,932,486
Common Stock Warrants [Member]    
Antidilutive Securities (in shares) 2,262,203 2,071,860
[1] Calculation assumes conversion of the stated value, and accrued dividends, of the Series F Preferred Stock into Common Stock at the Floor Price of $11.17.
[2] Calculation assumes exercise of the Series F Preferred Warrants for cash into Series F Preferred Stock and subsequent conversion of the Series F Preferred Stock into Common Stock at the Floor Price of $11.17.